India, Oct. 12 -- GLP-1 receptor agonists were initially "diabetes drugs" and then the "wonder weight-loss drugs." But the benefits don't stop there; recent research suggests significant benefits in cardiometabolic health, too.

The turning point was regulatory, almost by accident. "In 2008, the FDA mandated cardiovascular outcomes trials for diabetes drugs after earlier studies raised concerns that lowering blood sugar could actually be dangerous for the heart. Nobody expected GLP-1s to shine in these trials," Diabetologist Dr Suman Banerjee (MBBS, EDIC, FCCCM) tells Health Shots. As one researcher put it, no animal studies or even basic physiology suggested they would help the cardiovascular system.

A pooled meta-analysis of 60,000 pat...